<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="130">
  <stage>Registered</stage>
  <submitdate>20/02/2007</submitdate>
  <approvaldate>20/02/2007</approvaldate>
  <nctid>NCT00438061</nctid>
  <trial_identification>
    <studytitle>Effect of Abdominal Obesity on Lipoprotein Metabolism</studytitle>
    <scientifictitle>Effect of Weight Loss on Lipoprotein Metabolism in Abdominal Obesity</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>EC-256</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Obesity</healthcondition>
    <healthcondition>Dyslipidemia</healthcondition>
    <healthcondition>Insulin Resistance</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Other blood disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Behaviour - Weight loss by dietary restriction

Behaviour: Weight loss by dietary restriction


</interventions>
    <comparator />
    <control />
    <interventioncode>Behaviour</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Primary: Fractional catabolic and production rates of LDL-apoB and HDL-apoA-I (before and after 16 week treatments)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Secondary: Cholesterol; Triglyceride; LDL-cholesterol; Adipocytokines; Genetic polymorphism</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Obesity was defined as a body mass index (BMI) &gt;28kg/m2 and visceral visceral obesity
             (waist to hip ratio&gt; 1.0 or waist circumference &gt;100 cm)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Diabetes mellitus,

          -  Proteinuria,

          -  Hypothyroidism,

          -  Abnormal liver enzymes,

          -  Major systemic illness,

          -  A history of alcohol abuse,

          -  A family history of hyperlipidemia or premature coronary artery disease or were taking
             medication known to affect lipid metabolism.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/01/1995</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>The University of Western Australia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Abdominal obesity is strongly associated with dyslipidemia, which may account for the
      associated increased risk of atherosclerosis and coronary disease. Weight reduction is
      suggested to be a preferred and effective first-line strategy to correct lipid abnormalities,
      particularly in overweight/obese subjects. This improvement may be related to the effect of
      reduction in abdominal fat mass on apoB and apoA-I metabolism, but this remains to be fully
      demonstrated.

      Hypothesis: Reduction in abdominal fat mass by weight loss decreases apoB concentration and
      raises HDL-cholesterol chiefly by increasing LDL-apoB fractional catabolic rate (FCR), as
      well as decreasing HDL apoA-I, respectively.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00438061</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dick C Chan, PhD</name>
      <address>The University of Western Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>